Biosimilar Drugs – A New Treatment Option
Written by Thomas Willett, RPh MBA, Vice President of New Site Operations It’s no secret that the cost of health care in the United States has risen dramatically over the last several decades. Part of that increase is the development of new classes of drugs meant to treat previously hard-to-treat conditions. These new drug classes are […]